| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_79f0a9cf228ec5df422294a38aa0c896 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2853
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2008-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be27cc2abbde77dd80ecba8dec714fa9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53a5750e611cab0812fc18d7309984e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e85f7fc01428662b22d6ed9431dfd32a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ef62b5ab0997f0f78c2d04c4c6671dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de1f2ef6319d3a22823999794c1d27e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a64f00592b8af68d858a54dc89ad0d4 |
| publicationDate |
2014-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2008282900-B2 |
| titleOfInvention |
Pulsatile gastric retentive dosage forms |
| abstract |
Dosage forms for delayed and pulsed release of therapeutic agents into the stomach are described. The dosage forms are gastric retentive dosage forms that achieve release of the therapeutic agent into the stomach and upper gastrointestinal tract subsequent to administration of the dosage form. The dosage forms find particular use in administration of acid-labile active agents such as proton pump inhibitors, and in treating gastric acid secretion such as gastroesophageal reflux disease (GERD) and nocturnal acid breakthrough (NAB). |
| priorityDate |
2007-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |